Bank of New York Mellon Corp Invests $1.67 Million in Sana Biotechnology, Inc. $SANA

Key Points

• Bank of New York Mellon acquired 477,542 Sana Biotechnology shares worth approximately $1.67 million, representing about 0.17% of the company. Institutional investors collectively own 88.23% of SANA.
• Analyst sentiment remains generally positive, with a MarketBeat consensus rating of “Moderate Buy” and an average price target of $9.33, despite mixed individual rating changes.
• SANA opened at $3.45 and trades within a 52-week range of $2.61 to $6.55. Sana reported a quarterly loss of $0.13 per share, beating the estimated loss of $0.15.

Bank of New York Mellon Corp acquired a new stake in shares of Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 477,542 shares of the company's stock, valued at approximately $1,667,000. Bank of New York Mellon Corp owned approximately 0.17% of Sana Biotechnology as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. AQR Capital Management LLC lifted its stake in shares of Sana Biotechnology by 49.8% during the first quarter. AQR Capital Management LLC now owns 573,146 shares of the company's stock worth $963,000 after buying an additional 190,483 shares during the period. Woodline Partners LP increased its position in shares of Sana Biotechnology by 13.1% in the 1st quarter. Woodline Partners LP now owns 780,656 shares of the company's stock valued at $1,312,000 after acquiring an additional 90,515 shares during the period. Franklin Resources Inc. raised its stake in Sana Biotechnology by 86.8% in the 2nd quarter. Franklin Resources Inc. now owns 93,081 shares of the company's stock worth $254,000 after acquiring an additional 43,247 shares during the last quarter. Rhumbline Advisers lifted its position in Sana Biotechnology by 11.6% during the 2nd quarter. Rhumbline Advisers now owns 203,283 shares of the company's stock worth $555,000 after acquiring an additional 21,149 shares during the period. Finally, Prudential Financial Inc. purchased a new stake in Sana Biotechnology during the 2nd quarter valued at about $50,000. 88.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

SANA has been the subject of several research analyst reports. TD Cowen upgraded Sana Biotechnology to a "strong-buy" rating in a research note on Monday, August 24th. Weiss Ratings raised shares of Sana Biotechnology from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, July 23rd. Wall Street Zen cut shares of Sana Biotechnology from a "hold" rating to a "sell" rating in a research note on Monday, July 20th. Finally, Bank of America cut their price objective on shares of Sana Biotechnology from $7.00 to $6.00 and set a "buy" rating on the stock in a research note on Friday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Sana Biotechnology has a consensus rating of "Moderate Buy" and an average target price of $9.33.

Sana Biotechnology Stock Performance

Shares of NASDAQ SANA opened at $3.45 on Wednesday. The company has a market capitalization of $1.03 billion, a PE ratio of -4.54 and a beta of 2.12. The company's fifty day moving average price is $3.63 and its 200 day moving average price is $3.41. Sana Biotechnology, Inc. has a 1 year low of $2.61 and a 1 year high of $6.55.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.15) by $0.02. On average, equities analysts expect that Sana Biotechnology, Inc. will post -0.72 EPS for the current year.

Sana Biotechnology Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company's core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.

Want to see what other hedge funds are holding SANA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.